Mutations in the anti-sigma H factor RshA confer resistance to econazole and clotrimazole in Mycobacterium smegmatis

References

1. World Health Organization Global Tuberculosis Report Geneva: World Health organization; 2018
   [Google Scholar]
2. Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med 2017
   [Google Scholar]
3. Furin J, Diacon AH, Andries K. Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline. Int J Tuberc Lung Dis 2017; 21:4–5 [View Article]
   [Google Scholar]
4. Da Silva Ferreira ME, Colombo AL, Paulsen I, Ren Q, Wortman J et al. The ergosterol biosynthesis pathway, transporter genes, and azole resistance in Aspergillus fumigatus . Med Mycol 2005; 43:313–319 [View Article]
   [Google Scholar]
5. McLean KJ, Clift D, Lewis DG, Sabri M, Balding PR et al. The preponderance of P450s in the Mycobacterium tuberculosis genome. Trends Microbiol 2006; 14:220–228 [View Article]
   [Google Scholar]
6. Ouellet H, Johnston JB, Ortiz de Montellano PR. The Mycobacterium tuberculosis cytochrome P450 system. Arch Biochem Biophys 2010; 493:82–95 [View Article]
   [Google Scholar]
7. Capyk JK, Kalscheuer R, Stewart GR, Liu J, Kwon H et al. Mycobacterial cytochrome P450 125 (cyp125) catalyzes the terminal hydroxylation of C27 steroids. J Biol Chem 2009; 284:35534–35542 [View Article]
   [Google Scholar]
8. Ortega Ugalde S, Boot M, Commandeur JNM, Jennings P, Bitter W et al. Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets?. Appl Microbiol Biotechnol 2019
   [Google Scholar]
9. McLean KJ, Marshall KR, Richmond A, Hunter IS, Fowler K et al. Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes. Microbiology 2002; 148:2937–2949 [View Article]
   [Google Scholar]
10. Burguiere A, Hitchen PG, Dover LG, Dell A, Besra GS. Altered expression profile of mycobacterial surface glycopeptidolipids following treatment with the antifungal azole inhibitors econazole and clotrimazole. Microbiology 2005; 151:2087–2095 [View Article]
    [Google Scholar]
11. Ahmad Z, Sharma S, Khuller GK. In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv. FEMS Microbiol Lett 2005; 251:19–22 [View Article]
    [Google Scholar]
12. Ahmad Z, Sharma S, Khuller GK. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. FEMS Microbiol Lett 2006; 261:181–186 [View Article]
    [Google Scholar]
13. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393:537–544 [View Article]
    [Google Scholar]
14. Daffé M. The cell envelope of tubercle bacilli. Tuberculosis 2015; 95:S155–S158 [View Article]
    [Google Scholar]
15. DeJesus MA, Gerrick ER, Xu W, Park SW, Long JE et al. Comprehensive essentiality analysis of the Mycobacterium tuberculosis genome via saturating transposon mutagenesis. mBio 2017; 8: [View Article]
    [Google Scholar]
16. Carroll P, Parish T. Deletion of cyp125 confers increased sensitivity to azoles in Mycobacterium tuberculosis . PLoS One 2015; 10:e0133129 [View Article]
    [Google Scholar]
17. Warrilow AGS, Jackson CJ, Parker JE, Marczylo TH, Kelly DE et al. Identification, characterization, and Azole-binding properties of Mycobacterium smegmatis CYP164A2, a homolog of ML2088, the sole cytochrome P450 gene of Mycobacterium leprae . Antimicrob Agents Chemother 2009; 53:1157–1164 [View Article]
    [Google Scholar]
18. Seward HE, Roujeinikova A, McLean KJ, Munro AW, Leys D. Crystal structure of the Mycobacterium tuberculosis P450 CYP121-fluconazole complex reveals new azole drug-P450 binding mode. J Biol Chem 2006; 281:39437–39443 [View Article]
    [Google Scholar]
19. McLean KJ, Dunford AJ, Sabri M, Neeli R, Girvan HM et al. CYP121, CYP51 and associated redox systems in Mycobacterium tuberculosis: towards deconvoluting enzymology of P450 systems in a human pathogen. Biochem Soc Trans 2006; 34:1178–1182 [View Article]
    [Google Scholar]
20. Driscoll MD, McLean KJ, Cheesman MR, Jowitt TA, Howard M et al. Expression and characterization of Mycobacterium tuberculosis CYP144: common themes and lessons learned in the M. tuberculosis P450 enzyme family. Biochim Biophys Acta 1814; 2011:76–87
    [Google Scholar]
21. Milano A, Pasca MR, Provvedi R, Lucarelli AP, Manina G et al. Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5–MmpL5 efflux system. Tuberculosis 2009; 89:84–90 [View Article]
    [Google Scholar]
22. Briffotaux J, Huang W, Wang X, Gicquel B. MmpS5/MmpL5 as an efflux pump in Mycobacterium species. Tuberculosis 2017; 107:13–19 [View Article]
    [Google Scholar]
23. Vilcheze C, Morbidoni HR, Weisbrod TR, Iwamoto H, Kuo M et al. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis . J Bacteriol 2000; 182:4059–4067 [View Article]
    [Google Scholar]
24. Howell Wescott HA, Roberts DM, Allebach CL, Kokoczka R, Parish T. Imidazoles induce reactive oxygen species in Mycobacterium tuberculosis which is not associated with cell death. ACS Omega 2017; 2:41–51 [View Article]
    [Google Scholar]
25. Andries K, Villellas C, Coeck N, Thys K, Gevers T et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 2014; 9:e102135 [View Article]
    [Google Scholar]
26. Ioerger TR, Feng Y, Ganesula K, Chen X, Dobos KM et al. Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories. J Bacteriol 2010; 192:3645–3653 [View Article]
    [Google Scholar]
27. Park ST, Kang C-M, Husson RN. Regulation of the SigH stress response regulon by an essential protein kinase in Mycobacterium tuberculosis . Proc Natl Acad Sci U S A 2008; 105:13105–13110 [View Article]
    [Google Scholar]
28. Song T, Dove SL, Lee KH, Husson RN. RshA, an anti-sigma factor that regulates the activity of the mycobacterial stress response sigma factor SigH. Mol Microbiol 2003; 50:949–959 [View Article]
    [Google Scholar]
29. Kaushal D, Schroeder BG, Tyagi S, Yoshimatsu T, Scott C et al. Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative factor, SigH. Proc Natl Acad Sci U S A 2002; 99:8330–8335 [View Article]
    [Google Scholar]
30. Kumar S, Badireddy S, Pal K, Sharma S, Arora C et al. Interaction of Mycobacterium tuberculosis RshA and SigH is mediated by salt bridges. PLoS One 2012; 7:e43676 [View Article]
    [Google Scholar]
31. Riccardi G, Milano A, Pasca MR, Nies DH. Genomic analysis of zinc homeostasis in Mycobacterium tuberculosis . FEMS Microbiol Lett 2008; 287:1–7 [View Article]
    [Google Scholar]
32. HF N, Tan JL, Zin T, Yap SF, Ngeow YF. A mutation in anti-sigma factor MAB_3542c may be responsible for tigecycline resistance in Mycobacterium abscessus . J Med Microbiol 2018; 67:1676–1681
    [Google Scholar]
33. Di Capua CB, Belardinelli JM, Buchieri MV, Bortolotti A, Franceschelli JJ et al. Deletion of MSMEG_1350 in Mycobacterium smegmatis causes loss of epoxy-mycolic acids, fitness alteration at low temperature and resistance to a set of mycobacteriophages. Microbiology 2018; 164:1567–1582 [View Article]
    [Google Scholar]